BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. USO
5. AMC
6. MSFT
7. AMZN
8. ACN
9. FFAI
10. PAA

Go back to BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
Bioline RX Ltd Ordinary shares (AMEX: BLNEF) Delayed: 0.86 --0 (-0%)
Previous Close $0.86    52 Week High $1.54 
Open $1.64    52 Week Low $1.15 
Day High $0.86    P/E N/A 
Day Low $0.86    EPS $0.00 
Volume 1,500       

Bioline RX Ltd Ordinary shares (AMEX: BLNEF) Delayed: 0.86 --0 (-0%)
Previous Close $0.86    52 Week High $1.54 
Open $1.64    52 Week Low $1.15 
Day High $0.86    P/E N/A 
Day Low $0.86    EPS $0.00 
Volume 1,500       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 2.48 -0.01 (0.4%)
Previous Close $2.49    52 Week High $1.63 
Open $2.53    52 Week Low $0.71 
Day High $2.53    P/E N/A 
Day Low $2.45    EPS $0.00 
Volume 1,288       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 2.48 -0.01 (0.4%)
Previous Close $2.49    52 Week High $1.63 
Open $2.53    52 Week Low $0.71 
Day High $2.53    P/E N/A 
Day Low $2.45    EPS $0.00 
Volume 1,288